COMMUNIQUÉS West-GlobeNewswire

Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced that the [...]
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43 rd Annual J.P. Morgan [...]
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06/01/2025
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno- [...]
MannKind Expands Executive Leadership Team
06/01/2025
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD [...]
Kura Oncology Announces Senior Executive Promotions
06/01/2025
– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D. promoted to Chief Scientific Officer – – Stephen Dale, M.D., steps down as CMO and Head of R&D to prioritize personal health – SAN [...]
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and [...]
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
06/01/2025
Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven [...]
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
06/01/2025
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the [...]
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
06/01/2025
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks Overall, DNL343 was found to be safe and well tolerated [...]
HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share
06/01/2025
BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the “Company”) (NASDAQ: HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the “Offering”) with [...]
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
06/01/2025
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and [...]
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/01/2025
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today [...]
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual [...]
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
06/01/2025
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY ® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first [...]
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
06/01/2025
Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms [...]
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
06/01/2025
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 [...]

Pages